Fabbrica Italiana Sintetici

What Fabbrica Italiana Sintetici does

Fabbrica Italiana Sintetici (FIS) is an Italian contract development and manufacturing organization (CDMO) founded in 1957, headquartered in Montecchio Maggiore, and controlled by Bain Capital Private Equity (86%) with the Ferrari family holding the remaining 14%. The company operates three fully integrated manufacturing plants in Italy (Montecchio Maggiore, Lonigo, and Termoli) with approximately 3,000 m³ of GMP reactor capacity ranging from 10L to 18,000L, supported by commercial offices in Boston and Tokyo and representative offices in Shanghai and Mumbai. Its customer base spans roughly 60 countries.

FIS runs two integrated business lines: a Custom (CDMO) business serving innovative pharmaceutical and biotech companies across the full development cycle from synthetic process optimization and scale-up to commercial GMP manufacturing, and a Generics business supplying off-patent active pharmaceutical ingredients across multiple therapeutic classes. The technology stack is built around five proprietary platforms — High Potency API (HPAPI) manufacturing with containment systems, large-scale spray drying, continuous flow chemistry, Liquid Phase Peptide Synthesis (LPPS), and integrated biocatalysis — supported by roughly 270 R&D employees and academic collaborations with multiple Italian universities and the Horizon Europe Nextbase consortium.

The business model combines professional-services CDMO engagements (quote-based pricing tied to molecule complexity, scale, and development stage) with transaction-based generic API supply. FY2025 consolidated revenue was €879 million (+8.2% YoY), adjusted EBITDA reached €181 million (+24%), and operating cash generation rose to €207 million. The Custom business grew 14% in 2025, including diversification into the GLP1 segment, and the company is executing a Bain Capital-backed Next Level strategic plan targeting leadership in the European small-molecule CDMO market by 2028, funded in part by a €770 million Senior Secured Notes issuance completed in February 2026.

Name

Fabbrica Italiana Sintetici

Legal name

F.I.S. Fabbrica Italiana Sintetici S.p.A.

Website

https://fisvi.com

Company type

Private

Founded year

1957

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Fabbrica Italiana Sintetici is an Italian CDMO founded in 1957 that develops and manufactures small molecule active pharmaceutical ingredients and intermediates for innovative pharmaceutical, biotech, and generic drug companies across roughly 60 countries, operating three integrated Italian production sites.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule API Commercial Manufacturing (HLAGAHAB), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• API contract manufacturing
• Active pharmaceutical ingredients
• Small molecule CDMO
• Generic API production
• Pharmaceutical intermediates

Headquarters

HQ city

Montecchio Maggiore

HQ country

Italy

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. CDMO Custom Business: Contract Development and Manufacturing Organization services for pharmaceutical and biotech companies, including process development, scale-up, and commercial manufacturing of custom APIs. The custom business grew 14% in 2025 and is the primary driver of expansion, with increasing portfolio diversification including GLP1 segment.
2. Generic APIs: Development and manufacturing of generic active pharmaceutical ingredients for products no longer protected by patents. Portfolio covers therapeutic classes including anxiolytics, tranquilizers, controlled substances, anticonvulsants, antibacterials, anti-inflammatories, and ophthalmics. Supplies manufacturers in over 60 countries.
3. R&D Services: Research and development services including process optimization, analytical development, and technology transfer supporting the custom business and new molecule pipeline development.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Fabbrica Italiana Sintetici (FIS) is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops and manufactures small molecule active pharmaceutical ingredients (APIs) and intermediates, alongside a portfolio of generic APIs. The company serves innovator pharmaceutical/biotech firms with custom development and manufacturing services and supplies generic APIs to off-patent drug manufacturers globally.

Product overview

FIS operates as a CDMO (Contract Development and Manufacturing Organization) offering two integrated business lines: Custom business covering development services and manufacturing services for pharmaceutical and biotech partners, and a Generics portfolio supplying off-patent active pharmaceutical ingredients. The Custom business supports the entire development cycle from synthetic process optimization through scale-up to large-scale GMP production, while the Generics portfolio provides pharmaceutical-grade APIs across multiple therapeutic classes. Key technology platforms include High Potency (HPAPI), Spray Drying, Flow Chemistry, LPPS (Peptide Synthesis), and Biocatalysis. The company operates three integrated manufacturing plants in Italy with over 3,000 m³ of total reactor capacity.

Differentiator

Problem solved

Functional benefit

Products and services

• Custom API Development and Manufacturing Services

Quantifiable outcome

• Revenue growth of 8.2% YoY reaching €879 million in FY 2025
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• SQ InnovationcoreStrategic or Co-development Partner · 15 April 2026Strategic long-term supply agreement for pharmaceutical-grade furosemide API to support Lasix ONYU production (furosemide injection for heart failure treatment) and pipeline products across the United States, Europe, and global markets. Agreement includes certain exclusivity provisions, aligning with SQ Innovation's mission to deliver at-home treatment alternatives to hospitalizations for edema in adult heart failure patients.
• University of BolognaminorStrategic or Co-development PartnerAgreement with Prof. Luca Bernardi, Organic Chemistry Consultant, since 2016 for academic collaboration in chemistry research.
• University of TurinminorStrategic or Co-development PartnerPhD funding for research concerning 'Precipitation and Isolation of New Chemical Modalities' applied to peptides and RNA carriers, active since November 2025.
• University of PaduaminorStrategic or Co-development PartnerNRRP PhD funding to develop statistical methodologies applied to process optimization, launched in October 2023.
• University of TriesteminorStrategic or Co-development PartnerTwo NRRP PhD fundings for new Raman-based analytical methodologies for API detection in wastewater and equipment cleaning verification (since October 2023), and one PhD funding on AI and computational approaches to API biological activity profiling (since October 2024).
• Horizon Europe - Nextbase ProjectminorStrategic or Co-development PartnerSix PhD fundings to develop more sustainable methodologies in organometallic catalysis using non-noble metals. Consortium involving four academic institutions and one industrial partner, in place since October 2023.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Lonza Group: Swiss-headquartered global CDMO leader offering small-molecule API manufacturing, biologics, and cell & gene services. Comparable to FIS as a contract manufacturer serving pharma and biotech customers, though Lonza is far larger and more diversified across modalities.

Direct peers

• Siegfried Holding: Swiss CDMO specializing in small-molecule APIs and intermediates with integrated drug product capabilities. Closest direct comparable to FIS in terms of business mix (custom CDMO + generics), European footprint, and small-molecule focus.
• Recipharm: European CDMO offering API manufacturing and drug product services across multiple therapeutic categories. Directly comparable to FIS's custom and generics API manufacturing model, though with greater drug product (fill-finish) exposure.
• Cambrex: US-headquartered CDMO focused on small-molecule API development and manufacturing with facilities in the US and Europe. Highly comparable service offering (process R&D through commercial API manufacturing) and overlapping customer base of pharma/biotech innovators.
• Hovione: Portuguese CDMO specializing in small-molecule API development, HPAPI, spray drying, and particle engineering. Directly competes with FIS in advanced API technologies (HPAPI, spray drying) and serves similar innovative pharma customer base.
• Aenova Group: German CDMO providing solid dosage forms, sterile liquids, and API manufacturing. Comparable to FIS in European small-molecule CDMO positioning, with stronger drug product capabilities but similar pharma customer base.
• PolyPeptide Group: Swiss-listed CDMO specializing in peptide API manufacturing. Directly comparable to FIS's emerging peptide (LPPS) platform, though PolyPeptide is more specialized and purer-play on peptides vs FIS's diversified small-molecule focus.
• WuXi STA (WuXi AppTec): Chinese CDMO arm of WuXi AppTec offering small-molecule API development and manufacturing. Direct competitor to FIS in custom API services globally, with significant scale advantages and lower cost base; comparable customer base across innovative pharma.
• EUROAPI: French API manufacturer spun off from Sanofi, focused on small-molecule APIs and CDMO services. Comparable to FIS in API portfolio breadth across therapeutic categories and European manufacturing footprint, though EUROAPI is more generics-tilted.

Regional players

• Farmhispania Group: Spanish API manufacturer and CDMO offering small-molecule APIs with custom synthesis services. Comparable in business model to FIS's generics + custom API offering, though smaller scale and focused on Southern European/regional customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/f-i-s---fabbrica-italiana-sintetici
• Facebookfacebook.com/fabbricaitalianasintetici

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fabbrica Italiana Sintetici